Do analysts rate POAI or AGPU?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Axe Compute 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Does the media prefer POAI or AGPU?

In the previous week, Axe Compute had 6 more articles in the media than Predictive Oncology. MarketBeat recorded 7 mentions for Axe Compute and 1 mentions for Predictive Oncology. Axe Compute's average media sentiment score of 0.29 beat Predictive Oncology's score of 0.00 indicating that Axe Compute is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Predictive Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Axe Compute 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable earnings and valuation, VIVO or POAI?

Predictive Oncology has higher revenue and earnings than VivoPower PLC Ordinary Shares. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio VivoPower PLC Ordinary Shares $60K 1,017.02 -$12.79M N/A N/A Predictive Oncology $1.66M 17.03 -$12.66M -$13.50 N/A

Do analysts prefer VVPR or POAI?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Vivopower International 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has better earnings & valuation, VVPR or POAI?

Predictive Oncology has higher revenue and earnings than Vivopower International. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Vivopower International $61K 942.61 -$12.79M N/A N/A Predictive Oncology $1.66M 17.03 -$12.66M -$13.50 N/A

Do analysts rate POAI or BIRD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Predictive Oncology 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Allbirds 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Does the media refer more to POAI or BIRD?

In the previous week, Allbirds had 2 more articles in the media than Predictive Oncology. MarketBeat recorded 3 mentions for Allbirds and 1 mentions for Predictive Oncology. Allbirds' average media sentiment score of 1.17 beat Predictive Oncology's score of 0.00 indicating that Allbirds is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Predictive Oncology 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Allbirds 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Predictive Oncology (POAI) Competitors

$8.35 +0.31 (+3.86%)

As of 08/13/2026

Compare

POAI vs. AGPU, CHRN, VIVO, VVPR, and BIRD

Should you buy Predictive Oncology stock or one of its competitors? Predictive Oncology's main competitors and comparable companies include Axe Compute (AGPU), ChronoScale Corporation Common Stock (CHRN), VivoPower PLC Ordinary Shares (VIVO), Vivopower International (VVPR), and Allbirds (BIRD). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "internet services & infrastructure" industry.

How does Predictive Oncology compare to Axe Compute?

Predictive Oncology (NASDAQ:POAI) and Axe Compute (NASDAQ:AGPU) are both small-cap technology companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, analyst recommendations, valuation, media sentiment, institutional ownership, dividends, profitability and risk.

Predictive Oncology has a net margin of -5,065.23% compared to Axe Compute's net margin of -470,383.31%. Predictive Oncology's return on equity of -732.73% beat Axe Compute's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Axe Compute	-470,383.31%	-7,363.67%	-626.32%

Predictive Oncology has higher revenue and earnings than Axe Compute. Axe Compute is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	17.03	-$12.66M	-$13.50	N/A
Axe Compute	$120K	791.85	-$233.10M	-$8.18	N/A

In the previous week, Axe Compute had 6 more articles in the media than Predictive Oncology. MarketBeat recorded 7 mentions for Axe Compute and 1 mentions for Predictive Oncology. Axe Compute's average media sentiment score of 0.29 beat Predictive Oncology's score of 0.00 indicating that Axe Compute is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Predictive Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Axe Compute	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

9.0% of Predictive Oncology shares are held by institutional investors. Comparatively, 9.0% of Axe Compute shares are held by institutional investors. 1.2% of Predictive Oncology shares are held by insiders. Comparatively, 1.2% of Axe Compute shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Predictive Oncology has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Axe Compute has a beta of 3.44, meaning that its stock price is 244% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Axe Compute	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Predictive Oncology and Axe Compute tied by winning 6 of the 12 factors compared between the two stocks.

How does Predictive Oncology compare to ChronoScale Corporation Common Stock?

ChronoScale Corporation Common Stock (NASDAQ:CHRN) and Predictive Oncology (NASDAQ:POAI) are both small-cap technology companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, dividends, earnings, media sentiment, valuation, risk, analyst recommendations and institutional ownership.

In the previous week, ChronoScale Corporation Common Stock had 3 more articles in the media than Predictive Oncology. MarketBeat recorded 4 mentions for ChronoScale Corporation Common Stock and 1 mentions for Predictive Oncology. ChronoScale Corporation Common Stock's average media sentiment score of 0.89 beat Predictive Oncology's score of 0.00 indicating that ChronoScale Corporation Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
ChronoScale Corporation Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Predictive Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

ChronoScale Corporation Common Stock has a beta of 1, suggesting that its stock price has a similar volatility profile to the broader market.Comparatively, Predictive Oncology has a beta of 1.35, suggesting that its stock price is 35% more volatile than the broader market.

ChronoScale Corporation Common Stock has higher revenue and earnings than Predictive Oncology. ChronoScale Corporation Common Stock is trading at a lower price-to-earnings ratio than Predictive Oncology, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
ChronoScale Corporation Common Stock	$12.80M	5.82	-$11.69M	-$5.38	N/A
Predictive Oncology	$1.66M	17.03	-$12.66M	-$13.50	N/A

6.4% of ChronoScale Corporation Common Stock shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 6.9% of ChronoScale Corporation Common Stock shares are held by company insiders. Comparatively, 1.2% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

ChronoScale Corporation Common Stock currently has a consensus price target of $6.00, indicating a potential downside of 71.33%. Given ChronoScale Corporation Common Stock's stronger consensus rating and higher possible upside, research analysts plainly believe ChronoScale Corporation Common Stock is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
ChronoScale Corporation Common Stock	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

ChronoScale Corporation Common Stock has a net margin of -135.66% compared to Predictive Oncology's net margin of -5,065.23%. ChronoScale Corporation Common Stock's return on equity of -197.81% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
ChronoScale Corporation Common Stock	-135.66%	-197.81%	-74.17%
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

Summary

ChronoScale Corporation Common Stock beats Predictive Oncology on 11 of the 15 factors compared between the two stocks.

How does Predictive Oncology compare to VivoPower PLC Ordinary Shares?

VivoPower PLC Ordinary Shares (NASDAQ:VIVO) and Predictive Oncology (NASDAQ:POAI) are both small-cap technology companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations and media sentiment.

VivoPower PLC Ordinary Shares has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. VivoPower PLC Ordinary Shares' return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VivoPower PLC Ordinary Shares	N/A	N/A	N/A
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

VivoPower PLC Ordinary Shares has a beta of -0.7, indicating that its share price is 170% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, indicating that its share price is 35% more volatile than the broader market.

In the previous week, VivoPower PLC Ordinary Shares had 1 more articles in the media than Predictive Oncology. MarketBeat recorded 2 mentions for VivoPower PLC Ordinary Shares and 1 mentions for Predictive Oncology. VivoPower PLC Ordinary Shares' average media sentiment score of 1.47 beat Predictive Oncology's score of 0.00 indicating that VivoPower PLC Ordinary Shares is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
VivoPower PLC Ordinary Shares	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Predictive Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

15.8% of VivoPower PLC Ordinary Shares shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 2.3% of VivoPower PLC Ordinary Shares shares are held by insiders. Comparatively, 1.2% of Predictive Oncology shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

VivoPower PLC Ordinary Shares currently has a consensus price target of $10.00, suggesting a potential upside of 105.34%. Given VivoPower PLC Ordinary Shares' stronger consensus rating and higher probable upside, analysts plainly believe VivoPower PLC Ordinary Shares is more favorable than Predictive Oncology.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VivoPower PLC Ordinary Shares	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Predictive Oncology has higher revenue and earnings than VivoPower PLC Ordinary Shares.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VivoPower PLC Ordinary Shares	$60K	1,017.02	-$12.79M	N/A	N/A
Predictive Oncology	$1.66M	17.03	-$12.66M	-$13.50	N/A

Summary

VivoPower PLC Ordinary Shares beats Predictive Oncology on 11 of the 14 factors compared between the two stocks.

How does Predictive Oncology compare to Vivopower International?

Vivopower International (NASDAQ:VVPR) and Predictive Oncology (NASDAQ:POAI) are both small-cap technology companies, but which is the better stock? We will contrast the two companies based on the strength of their valuation, institutional ownership, risk, earnings, analyst recommendations, dividends, media sentiment and profitability.

Predictive Oncology has higher revenue and earnings than Vivopower International.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vivopower International	$61K	942.61	-$12.79M	N/A	N/A
Predictive Oncology	$1.66M	17.03	-$12.66M	-$13.50	N/A

Vivopower International has a net margin of 0.00% compared to Predictive Oncology's net margin of -5,065.23%. Vivopower International's return on equity of 0.00% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Vivopower International	N/A	N/A	N/A
Predictive Oncology	-5,065.23%	-732.73%	-235.55%

15.8% of Vivopower International shares are held by institutional investors. Comparatively, 9.0% of Predictive Oncology shares are held by institutional investors. 9.1% of Vivopower International shares are held by company insiders. Comparatively, 1.2% of Predictive Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Vivopower International has a beta of -1.65, indicating that its stock price is 265% less volatile than the broader market. Comparatively, Predictive Oncology has a beta of 1.35, indicating that its stock price is 35% more volatile than the broader market.

In the previous week, Predictive Oncology had 1 more articles in the media than Vivopower International. MarketBeat recorded 1 mentions for Predictive Oncology and 0 mentions for Vivopower International. Vivopower International's average media sentiment score of 0.00 equaled Predictive Oncology'saverage media sentiment score.

Company	Overall Sentiment
Vivopower International	Neutral
Predictive Oncology	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Vivopower International	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Vivopower International beats Predictive Oncology on 6 of the 10 factors compared between the two stocks.

How does Predictive Oncology compare to Allbirds?

Predictive Oncology (NASDAQ:POAI) and Allbirds (NASDAQ:BIRD) are both small-cap technology companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, risk, valuation, profitability, media sentiment, earnings, analyst recommendations and dividends.

Predictive Oncology has higher earnings, but lower revenue than Allbirds. Predictive Oncology is trading at a lower price-to-earnings ratio than Allbirds, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Predictive Oncology	$1.66M	17.03	-$12.66M	-$13.50	N/A
Allbirds	$152.47M	0.15	-$77.28M	-$9.12	N/A

Predictive Oncology has a beta of 1.35, meaning that its stock price is 35% more volatile than the broader market. Comparatively, Allbirds has a beta of 2.58, meaning that its stock price is 158% more volatile than the broader market.

Allbirds has a net margin of -53.36% compared to Predictive Oncology's net margin of -5,065.23%. Allbirds' return on equity of -173.54% beat Predictive Oncology's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Predictive Oncology	-5,065.23%	-732.73%	-235.55%
Allbirds	-53.36%	-173.54%	-67.54%

In the previous week, Allbirds had 2 more articles in the media than Predictive Oncology. MarketBeat recorded 3 mentions for Allbirds and 1 mentions for Predictive Oncology. Allbirds' average media sentiment score of 1.17 beat Predictive Oncology's score of 0.00 indicating that Allbirds is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Predictive Oncology	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Allbirds	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Predictive Oncology	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Allbirds	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

9.0% of Predictive Oncology shares are owned by institutional investors. Comparatively, 44.1% of Allbirds shares are owned by institutional investors. 1.2% of Predictive Oncology shares are owned by insiders. Comparatively, 30.7% of Allbirds shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Allbirds beats Predictive Oncology on 12 of the 14 factors compared between the two stocks.

Get Predictive Oncology News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding POAI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

POAI vs. The Competition

Export

Metric	Predictive Oncology	IT Services Industry	Technology Sector	NASDAQ Exchange
Market Cap	$28.34M	$11.55B	$30.69B	$13.10B
Dividend Yield	N/A	2.80%	2.73%	10.45%
P/E Ratio	-0.62	14.06	75.56	25.28
Price / Sales	17.03	64.27	600.24	87.71
Price / Cash	N/A	45.91	53.72	50.90
Price / Book	-18.15	24.51	9.57	6.24
Net Income	-$12.66M	$271.20M	$681.19M	$347.60M
7 Day Performance	-0.36%	2.17%	1.44%	1.07%
1 Month Performance	19.12%	2.97%	2.33%	1.03%
1 Year Performance	-36.02%	36.05%	199.49%	20.77%

Predictive Oncology Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
POAI Predictive Oncology	0.0389 of 5 stars	$8.35 +3.9%	N/A	-38.4%	$28.34M	$1.66M	N/A	30	News Coverage
AGPU Axe Compute	0.3664 of 5 stars	$9.19 +2.0%	N/A	N/A	$105.59M	$120K	N/A	13	News Coverage Earnings Report Short Interest Increase
CHRN ChronoScale Corporation Common Stock	0.8748 of 5 stars	$24.86 +1.7%	$6.00 -75.9%	+542.4%	$88.50M	$12.80M	N/A	60	Positive News Short Interest Decrease Gap Up
VIVO VivoPower PLC Ordinary Shares	2.7234 of 5 stars	$3.95 +1.3%	$10.00 +153.2%	N/A	$49.49M	$60K	N/A	41
VVPR Vivopower International	0.0195 of 5 stars	$3.73 +4.5%	N/A	-27.9%	$46.73M	$61K	N/A	240

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:POAI) was last updated on 8/14/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Predictive Oncology (POAI) Competitors

POAI vs. AGPU, CHRN, VIVO, VVPR, and BIRD

How does Predictive Oncology compare to Axe Compute?

Summary

How does Predictive Oncology compare to ChronoScale Corporation Common Stock?

Summary

How does Predictive Oncology compare to VivoPower PLC Ordinary Shares?

Summary

How does Predictive Oncology compare to Vivopower International?

Summary

How does Predictive Oncology compare to Allbirds?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POAI vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Predictive Oncology (POAI) Competitors

POAI vs. AGPU, CHRN, VIVO, VVPR, and BIRD

How does Predictive Oncology compare to Axe Compute?

Is POAI or AGPU more profitable?

Which has better earnings and valuation, POAI or AGPU?

Does the media prefer POAI or AGPU?

Do institutionals and insiders hold more shares of POAI or AGPU?

Which has more volatility & risk, POAI or AGPU?

Do analysts rate POAI or AGPU?

Summary

How does Predictive Oncology compare to ChronoScale Corporation Common Stock?

Does the media favor CHRN or POAI?

Which has more risk & volatility, CHRN or POAI?

Which has better valuation & earnings, CHRN or POAI?

Do institutionals & insiders believe in CHRN or POAI?

Do analysts recommend CHRN or POAI?

Is CHRN or POAI more profitable?

Summary

How does Predictive Oncology compare to VivoPower PLC Ordinary Shares?

Is VIVO or POAI more profitable?

Which has more volatility & risk, VIVO or POAI?

Does the media favor VIVO or POAI?

Do institutionals and insiders have more ownership in VIVO or POAI?

Do analysts recommend VIVO or POAI?

Which has preferable earnings and valuation, VIVO or POAI?

Summary

How does Predictive Oncology compare to Vivopower International?

Which has better earnings & valuation, VVPR or POAI?

Is VVPR or POAI more profitable?

Do insiders & institutionals have more ownership in VVPR or POAI?

Which has more volatility and risk, VVPR or POAI?

Does the media favor VVPR or POAI?

Do analysts prefer VVPR or POAI?

Summary

How does Predictive Oncology compare to Allbirds?

Which has preferable earnings & valuation, POAI or BIRD?

Which has more volatility and risk, POAI or BIRD?

Is POAI or BIRD more profitable?

Does the media refer more to POAI or BIRD?

Do analysts rate POAI or BIRD?

Do insiders and institutionals hold more shares of POAI or BIRD?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

POAI vs. The Competition

Predictive Oncology Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools